Supreme Court lets Matrixx investor suit go forward

The U.S. Supreme Court has ruled against Matrixx Initiatives, allowing a class-action lawsuit by investors to go forward after the company failed to disclose initial reports of consumers who experienced adverse side effects. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.